Want to join the conversation?
Global pharmaceutical company $PFE today announced that it has closed the $130MM worth acquisition of $GSK's quadrivalent meningitis ACWY vaccines Nimenrix and Mencevax. When the deal was announced on June 22, 2015, $PFE said that it does not expect any significant impact on its 2015 financial performance from this transaction.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?